Cover Image
市場調查報告書

Targovax AS的產品平台分析

Targovax AS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321962
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Targovax AS的產品平台分析 Targovax AS - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 32 Pages
簡介

Targovax AS是總公司設立於挪威的製藥企業,致力於開發腫瘤疫苗。擁有主動免疫療法用癌症疫苗的開發、隨著未滿足需求,配合廣泛適應症之抗癌用免疫醫藥品等平台產品。

本報告提供Targovax AS 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Targovax AS 基本資料

  • Targovax AS 概要
  • 主要資訊
  • 企業資料

Targovax AS :R&D概要

  • 主要的治療範圍

Targovax AS :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Targovax AS :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Targovax AS :藥物簡介

  • TG-01
  • TG-02
  • TG-03

Targovax AS :開發平台分析

  • 各給藥途徑
  • 各分子類型

Targovax AS :最新的開發平台資訊

Targovax AS :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07929CDB

Summary

Global Markets Direct's, 'Targovax AS - Product Pipeline Review - 2015', provides an overview of the Targovax AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Targovax AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Targovax AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Targovax AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Targovax AS's pipeline products

Reasons to buy

  • Evaluate Targovax AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Targovax AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Targovax AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Targovax AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Targovax AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Targovax AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Targovax AS Snapshot
    • Targovax AS Overview
    • Key Information
    • Key Facts
  • Targovax AS - Research and Development Overview
    • Key Therapeutic Areas
  • Targovax AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Targovax AS - Pipeline Products Glance
    • Targovax AS - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Targovax AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Targovax AS - Drug Profiles
    • TG-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-402
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-802
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONCOS-902
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Targovax AS - Pipeline Analysis
    • Targovax AS - Pipeline Products by Target
    • Targovax AS - Pipeline Products by Route of Administration
    • Targovax AS - Pipeline Products by Molecule Type
    • Targovax AS - Pipeline Products by Mechanism of Action
  • Targovax AS - Recent Pipeline Updates
  • Targovax AS - Dormant Projects
  • Targovax AS - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Targovax AS, Key Information
  • Targovax AS, Key Facts
  • Targovax AS - Pipeline by Indication, 2015
  • Targovax AS - Pipeline by Stage of Development, 2015
  • Targovax AS - Monotherapy Products in Pipeline, 2015
  • Targovax AS - Phase II, 2015
  • Targovax AS - Phase I, 2015
  • Targovax AS - Preclinical, 2015
  • Targovax AS - Discovery, 2015
  • Targovax AS - Pipeline by Target, 2015
  • Targovax AS - Pipeline by Route of Administration, 2015
  • Targovax AS - Pipeline by Molecule Type, 2015
  • Targovax AS - Pipeline Products by Mechanism of Action, 2015
  • Targovax AS - Recent Pipeline Updates, 2015
  • Targovax AS - Dormant Developmental Projects,2015
  • Targovax AS, Subsidiaries

List of Figures

  • Targovax AS - Pipeline by Top 10 Indication, 2015
  • Targovax AS - Pipeline by Stage of Development, 2015
  • Targovax AS - Monotherapy Products in Pipeline, 2015
  • Targovax AS - Pipeline by Top 10 Target, 2015
  • Targovax AS - Pipeline by Top 10 Route of Administration, 2015
  • Targovax AS - Pipeline by Top 10 Molecule Type, 2015
  • Targovax AS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top